Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.

The entities involved

• Alnylam Pharmaceuticals →

  biopharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Sun 05:14
• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12
• Jeffrey Yu →

  researcher

  Nothing else this week.

• MarketBeat →

  American personal finance blog

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • MarketBeat aggregates data on IDT Corporation stock performance.Mon 17:15

Related events

• Insider trading disclosures made via SEC filings for company Evolus, reported on September 1, 2026.Sep 5
• Benchmark and Booking Holdings disclosed insider trading filings while also restating ratings and raising price targets.Sep 2
• Astera Labs disclosed insider transactions via SEC filings while trading on the Nasdaq stock exchange.Sep 4
• Analyst reports are driving consensus ratings and price targets for Tsakos Energy Navigation Ltd, which is also required to disclose insider trading activity with the SEC.Sep 22
• Insider trading disclosures filed with the SEC by IRADIMED CORPORATION on July 31, 2026.Aug 1